CACA and CPSA, The Winning Partners – CPSA USA 2019
Chinese American Chromatography Association (CACA) is very pleased to play an active role in the 22nd Annual Symposium on Clinical and Pharmaceutical Solutions through Analysis (CPSA USA 2019) which was hold October 28 - 31, 2019, at Sheraton Bucks County, Langhorne, PA. There were over 350 participants attending this world-renowned symposium focusing on lively discussions, memorable interactions, and the sharing of real-world experiences that focused on the unique challenges facing the modern analytical laboratory and the risks – and reality – of personalized healthcare. This marked the third year in a row that CACA hosted sessions at CPSA USA. CACA is one of the official CPSA partners and we had a table booth at exhibition session.
This annual CPSA meeting began in 1998 and was the first industry-led event to complement academic-based meetings and address the specific needs of industry researchers. Since then, CPSA series meetings have expanded to include annual CPSA Shanghai where CACA has been an important partner in the last a couple of years, annual CPSA Europe, and annual CPSA Brazil.
The CACA, founded in 2008, is a tax-exempt non-profit organization. It is composed of over one thousand enthusiastic scientists mainly residing in North America and China with interests in separation science such as sample preparation, LC, GC, SFC, spectroscopy, and MS. Our members come from industry, government, and academia with a goal of social networking, information exchange, and experience sharing in chromatography technology and practice. The CACA hosts dinner meetings, webinars/virtual symposiums (20 webinars since 2016, visit http://ca-ca.org/index.php/webinar for past and future webinars), and workshops each year to provide networking opportunities and to foster information sharing among its members. CACA also presents annual awards for outstanding young scientists and graduate students.
On behalf of CACA, Dr. Chuping Luo of Advanced Materials Technology, the Immediate Past President of CACA, and Dr. Naidong Weng of Janssen R&D, the President Elect of CACA, organized two CACA sessions in CPSA USA 2019. Many CACA Executive Committee members, especially Dr. Xiang Zhang at the University of Louisville, the President of CACA, provided wonderful supports.
On Tuesday morning (October 29, 10-11:45AM), a joint session titled with “CACA and CPSA, The Winning Partner” featured three distinguished speakers.
- Using Superficially Porous Particle Technology for HPLC Method Modernization & Development
Dr. Stephanie Schuster, Advanced Materials Technology (AMT)
- Novel Strategy for Sensitive Analytical Method Development Based on HPLC-MS
Dr. Hongyue Guo, Bristol-Myers Squibb (BMS)
- Determining Cyclooxygenase Selectivity in Human Whole Blood Assay and Optimizing Assay Conditions Utilizing LC-MS/MS
Dr. Yifan Shi, Janssen R&D
The conference room was completed full and additional chairs were arranged. Still there were a few standing audiences. The contents of the presentations are excellent with very useful practical examples. Audiences were highly engaged. The session was scheduled for one hour and 45 min but lasted for over two and half hours (CPSA is famous for lively and relaxed exchange of discussion during presentations to maximize the interaction and learning – those of us who are long-time CPSA attendees fondly called it CPSA Time) and audiences still did not want to leave even during the lunch hour.
On Thursday afternoon (October 31, 1:30-3PM), the last session of CPSA, CACA hosted the session titled with “Presentations from the Edge: Young Scientist Session” with three outstanding young scientists.
- High Resolution Mass Spectrometry and Isotope Tracing to Probe Lipid Metabolism
Dr. Erik Allman, Janssen R&D/Penn State University
- Sensitive Antibody Free Strategies for Targeted Protein Quantification in Biomatrices
Dr. Bo An, GlaxoSmithKline (GSK)
- Development of A Streamlined Workflow for Quantitative Analysis of Antisense Oligonucleotide
Dr. Fengjian Shi, Biogen
The speakers presented the cutting-edge technology on tackling some of the most challenging analytical issues – metabolomics, protein bioanalysis, as well as analysis and method transfer of oligonucleotides. Audiences were so engaged in the discussion and they forgot this was the last session of the symposium. Certificates were awarded to all three young scientists.
Indeed, CACA and CPSA are the Winning Partners. We would like sincerely to thank CPSA founder Dr. Mike Lee of Milestone Development Services and CPSA Organization Committee, especially CPSA USA 2019 co-chairs, Dr. Timothy Olah of Bristol-Myers Squibb and Dr. Neil Spooner of Spooner Bioanalytical Solution, for their wonderful collaboration. Kudos also go to Emily Ehrenfeld and Carla Marshall-Waggett of New Objective for their continuous support to CACA. We are looking forward to future and more expanded partnership – at CPSA USA and China.
Finally, we would like to invite our members to participate the upcoming CACA events at Eastern Analytical Symposium (EAS) and CPSA Shanghai 2020 and to solicit nominations and/or self-nominations for the CACA Student Excellence Awards and Young Investigator Award. We would also sincerely acknowledge contributions from our sponsors for their yearly support.
Please register for
Nov 13, 2019 12:00 PM EST at:
Andrew Harron, Ph.D
Applications Research Scientist
Advanced Materials Technology
The landscape for new biological drug development continues to evolve in complexity. With biosimilars entering the market and originator products coming off patent, the competitive race for market dominance is reliant on:
- A deeper understanding of the drug product to produce a more comprehensive drug filing in order to delay or prevent market entrance by a competitor.
- A more thorough characterization of an innovator product or proposed biosimilar in order to take full advantage of the Regulatory pathways to rapid approval
Pharmaceutical companies employ many orthogonal techniques and methodologies to better develop a complete picture of biopharmaceuticals which are inherently more complex than small molecules. The use of various separation technologies in the analysis of biological drugs is pervasive in the overall new product development. While not all separations involve HPLC, most do and would benefit from the unique characteristics of superficially porous particle columns. This webinar will walk through the biological drug development process, while focusing on the unique separation needs of biologicals, including a conversation on intact and reduced mAb mass analysis by LC/MS. The webinar will also demonstrate a way to develop an understanding of the protein backbone via peptide mapping and glycosylation while emphasizing areas in the workflow where superficially porous particle columns with appropriate pore sizes offer a unique advantage.
Key Learning Objectives:
- Why is it important to fully characterize a new or biosimilar product?
- What is required to fully characterize a biopharmaceutical product?
- How to enable the characterization of a biopharmaceutical product through better chromatography?
Who Should Attend:
- Separation scientists involved in developing LC and LC/MS characterization methods of biopharmaceutical products and those interested in learning more about separation.
After registering, you will receive a confirmation email containing information about joining the webinar.